The effect of freeze/thaw cycles on the stability of compounds in DMSO

被引:77
作者
Kozikowski, BA [1 ]
Burt, TM [1 ]
Tirey, DA [1 ]
Williams, LE [1 ]
Kuzmak, BR [1 ]
Stanton, DT [1 ]
Morand, KL [1 ]
Nelson, SL [1 ]
机构
[1] Procter & Gamble Pharmaceut, High Throughput Screening Lab, Mason, OH 45040 USA
关键词
mass spectrometry (MS); high-performance liquid chromatography-mass spectrometry (HPLC-MS); pharmaceutical drug discovery; compound repository; compound stability; high-throughput screening (HTS);
D O I
10.1177/1087057103252618
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A diverse set of 320 compounds from the Procter & Gamble Pharmaceuticals organic compound repository was prepared as 20-mM DMSO solutions and stored at 4degreesC under argon in pressurized canisters to simulate a low-humidity environment. The plates were subjected to 25 freeze/thaw cycles while being exposed to ambient atmospheric conditions after each thaw to simulate the time and manner by which compound plates are exposed to the atmosphere during typical liquid-handling and high-throughput screening processes. High-performance liquid chromatography-mass spectrometry with evaporative light-scattering detection was used to quantitate the amount of compound remaining after every 5th freeze/thaw cycle. Control plates were stored either at room temperature under argon or at 4degreesC under argon without freeze/thaw cycling and were evaluated at the midpoint and the endpoint of the study. The study was conducted over a short time period (i.e., 7 weeks) to minimize the effect of compound degradation over time due to the exposure of the compounds to DMSO. The results from this study will be used to determine the maximum number of freeze/thaw cycles that can be achieved while maintaining acceptable compound integrity.
引用
收藏
页码:210 / 215
页数:6
相关论文
共 12 条
[1]  
[Anonymous], 1999, APPL MULTIVARIATE AN
[2]  
APERGHIS PN, 1999, LAB AUT 99 SAN DIEG
[3]  
COCKBURNPRICE S, 2001, DRUG DISCOV DEV NOV, P81
[4]  
Darvas F, 2000, GENET ENG NEWS, V20, P30
[5]  
HEATON Z, 2001, 7 ANN C SOC BIOM SCR
[6]  
KOZIKOWSKI BA, 2001, 7 ANN C SOC BIOM SCR
[7]  
*MIN INC, MIN WIND REL 12 23
[8]  
NIE D, 1998, 4 ANN C SOC BIOM SCR
[9]  
PEARLMAN RS, 1997, 3D QSAR DRUG DESIGN, V2, P339
[10]  
*SAS I, SAS REL 8 0